Modeling congenital cataract in vitro using patient-specific induced pluripotent stem cells

Congenital cataracts are the leading cause of childhood blindness. To date, surgical removal of cataracts is the only established treatment, but surgery is associated with multiple complications, which often lead to visual impairment. Therefore, mechanistic studies and drug-candidate screening have...

Full description

Saved in:
Bibliographic Details
Published in:npj Regenerative medicine 2021-10, Vol.6 (1), p.1-14, Article 60
Main Authors: Lyu, Danni, Zhang, Lifang, Qin, Zhenwei, Ni, Shuang, Li, Jiayong, Lu, Bing, Hao, Shengjie, Tang, Qiaomei, Yin, Houfa, Chen, Zhijian, Yan, Yong-Bin, Ji, Junfeng, He, Jiliang, Nagy, Andras, Fu, Qiuli, Yao, Ke
Format: Article
Language:English
Subjects:
692/308/1426
692/308/2171
692/699/3161/3168
Biomaterials
Biomedical and Life Sciences
Biomedicine
Cataracts
Cell Biology
Congenital diseases
Immunology
Proteins
Regenerative Medicine/Tissue Engineering
Stem Cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Congenital cataracts are the leading cause of childhood blindness. To date, surgical removal of cataracts is the only established treatment, but surgery is associated with multiple complications, which often lead to visual impairment. Therefore, mechanistic studies and drug-candidate screening have been intrigued by the aims of developing novel therapeutic strategies. However, these studies have been hampered by a lack of an appropriate human-disease model of congenital cataracts. Herein, we report the establishment of a human congenital cataract in vitro model through differentiation of patient-specific induced pluripotent stem cells (iPSCs) into regenerated lenses. The regenerated lenses derived from patient-specific iPSCs with known causative mutations of congenital cataracts ( CRYBB2 [p. P24T] and CRYGD [p. Q155X]) showed obvious opacification that closely resembled that seen in patients’ cataracts in terms of opacification severity and disease course accordingly, as compared with lentoid bodies (LBs) derived from healthy individuals. Increased protein aggregation and decreased protein solubility corresponding to the patients’ cataract severity were observed in the patient-specific LBs and were attenuated by lanosterol treatment. Taken together, the in vitro model described herein, which recapitulates patient-specific clinical manifestations of congenital cataracts and protein aggregation in patient-specific LBs, provides a robust system for research on the pathological mechanisms of cataracts and screening of drug candidates for cataract treatment.
ISSN:2057-3995
2057-3995
DOI:10.1038/s41536-021-00171-x